In breast carcinoma cells, adriamycin-induced TRPC5 upregulation protects them from chemotherapy treatment, by inducing autophagy via an increase in cytosolic Ca2+ concentrations and activation of the Ca2+-dependent CaMKKβ/AMPKα/mTOR pathway, promoting the cancer cell survival and tumour growth in vivo [200] (Figure 2). This evidence concerns the gene TRPC5 and breast carcinoma.